leadf
logo-loader
viewBiomedican

Biomedican Inc's organic, non-GMO CBD compound set for large-scale production in 2021

Biomedican Inc Chief Investment Officer Dennis O'Neill tells Proactive the Fremont, California-based CBD-focused group is focusing on commercializing its organic, non-GMO CBD compound.

O'Neill says because its CBD product produces 0.0% THC, it opens up distribution channels for the group. The group is expected to begin large-scale production in 2021.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Marble Financial’s subsidiary Inverite Verification records 80,000 monthly...

Marble Financial CEO Karim Nanji joined Steve Darling from Proactive to share news its subsidiary, Inverite Verification has reported achieved record growth and transaction volume milestones. Nanji telling Proactive in August the company surpassed 80,000 monthly transactions and recorded an...

7 minutes ago

2 min read